Items Tagged ‘gilotrif’

November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


September 22nd, 2015

Gilotrif Improves Outcomes in Lung Cancer

By

The targeted agent Gilotrif (afatinib) improves outcomes compared to Tarceva (erlotinib) among patients with squamous cell lung cancer. These results were recently published in The Lancet Oncology. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, NSCLC accounts for 75–80% of all lung cancers. Although progress has been made in […]

View full entry

Tags: afatinib, EGFR-positive, General Lung Cancer, gilotrif, Lung Cancer, News, squamous cell lung cancer, targeted agent


August 5th, 2014

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors

By

Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had stopped responding to the EGFR inhibitors Tarceva® (erlotinib) and Iressa® (gefitinib). This novel combination appeared to benefit patients regardless of whether their […]

View full entry

Tags: EGFR, erbitux, gilotrif, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell